Nazmeen Aarifa, Maiti Smarajit, Mandal Kusumita, Roy Samir K, Ghosh Tamal K, Sinha Nirmalya K, Mandal Kamalika
Department of Biochemistry, Cell & Molecular Therapeutics Lab, Oriental Institute of Science & Technology, Midnapore. India.
Department of Biochemistry and Biotechnology, Cell & Molecular Therapeutics Lab, OIST, Midnapore- 721102. India.
Med Chem. 2017;13(8):796-804. doi: 10.2174/1573406413666170424155452.
Both ovarian/breast cancers are the most prevalent hormone-associated gynecological-cancers, where uncontrolled cellular proliferations/genetic-errors are noticed. The cancer-antigen125 (CA125), which we assessed presently is an important biomarker in the early detection/monitoring of this disease-pathogenesis.
Serum/tissue CA125 was measured by solid-phase-Enzyme-linked-immunosorbentassay in women with ovarian/breast tumors of different types (epithelial/non-epithelial; benign/ borderline/ malignant)/stages. Breast-tumor tissues were employed for histoarchitecture/DNAstability (comet) assay. Extensive protein-protein(CA125) interactions were studied by the STRING (Search-Tool-for-the-Retrieval-of-Interacting Genes/Proteins) Bioinformatics-software.
Serum CA125 levels were <35 U/ml in 94% of benign epithelial-cases, 35-65 U/ml in 100% of borderline-tumors and >100 U/ml in the 41.17% of patients with malignant-tumors. The malignant epithelial tumor showed significantly higher (>100U/ml) CA125 than the non-epithelial malignant-tumor (<35-65 U/ml). Highly enhanced cellularity/histo-architectural impairment/unstable- DNA-materials/CA125 was found in advanced breast-cancers. The CA125 is highly metabolically interactive, especially with mesothelin impairing cell-cell adhesion and enhancing tissue anti-establishment.
CA125 is a predictive-marker in ovarian/breast carcinoma depending on disease nature/stages. CA125, in combination with other tests like mesothelin/estradiol can be of great use in the better diagnosis of this disease. Not only as a detection-marker, has the CA125 played an interactive role in the disease processes. The Bioinformatics study revealed an important role of mesothelin and other mucin like proteins. Early detection and proper diagnosis are important determinants for the greater possibility of the relief from the disease like cancers. Selection of suitable biomarker combinations may increase the better diagnosis of the types and severity of this disease. Our present result has an impact on these aspects.
卵巢癌和乳腺癌都是最常见的激素相关妇科癌症，其特征是细胞增殖失控和基因错误。我们目前评估的癌抗原125（CA125）是该疾病发病机制早期检测和监测中的一种重要生物标志物。
采用固相酶联免疫吸附测定法测量不同类型（上皮性/非上皮性；良性/交界性/恶性）/分期的卵巢肿瘤和乳腺肿瘤女性患者的血清/组织CA125。乳腺肿瘤组织用于组织结构/DNA稳定性（彗星）分析。通过STRING（搜索相互作用基因/蛋白质的工具）生物信息学软件研究广泛的蛋白质-蛋白质（CA125）相互作用。
94%的良性上皮性病例血清CA125水平<35 U/ml，100%的交界性肿瘤血清CA125水平为35 - 65 U/ml，41.17%的恶性肿瘤患者血清CA125水平>100 U/ml。恶性上皮性肿瘤的CA125水平（>100 U/ml）显著高于非上皮性恶性肿瘤（<35 - 65 U/ml）。在晚期乳腺癌中发现细胞数量高度增加、组织结构受损、DNA物质不稳定以及CA125水平升高。CA125具有高度的代谢相互作用，尤其是与间皮素相互作用，会损害细胞间粘附并增强组织抗形成能力。
CA125是卵巢癌和乳腺癌中取决于疾病性质/分期的预测标志物。CA125与间皮素/雌二醇等其他检测方法联合使用，对该疾病的更好诊断可能有很大帮助。CA125不仅作为检测标志物，还在疾病过程中发挥了相互作用的作用。生物信息学研究揭示了间皮素和其他黏蛋白样蛋白质的重要作用。早期检测和正确诊断是提高癌症等疾病缓解可能性的重要决定因素。选择合适的生物标志物组合可能会更好地诊断该疾病的类型和严重程度。我们目前的结果在这些方面具有重要意义。
